MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for people living with endocrine and metabolic disorders. Its proprietary Precision Endocrine Peptide (PEP) platform engineers long-acting peptide prodrugs, and its pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, MBX 4291 for obesity, and MBX 5765 for post-bariatric hypoglycemia. The company is publicly traded on Nasdaq under the ticker MBX.
Backed by: norwest-venture-partners — https://mbxbio.com
As a clinical-stage biotech, MBX Biosciences publishes no public API, developer portal, SDKs, or technical documentation surface. This profile is maintained for network completeness; the enrichment pass captured a domain-security probe of mbxbio.com.